In this context, Janostiak and coworkers showed that both B-RAF kinase inhibitor (Vemurafenib) plus anaplastic lymphoma kinase (ALK) inhibitor (Ceritinib) resistant A375 melanoma cells isolated from xenograft mice are sensitive to AT-101 treatment. The gene discussed is ALK; the disease is melanoma.